Related Experiment Video
Updated: Nov 1, 2025

Intravitreal Injection and Quantitation of Infection Parameters in a Mouse Model of Bacterial Endophthalmitis
Published on: February 6, 2021
Endogenous fungal endophthalmitis following intensive corticosteroid therapy in severe COVID-19 disease
Daraius Shroff1, Ritesh Narula2, Neelam Atri1
1Shroff Eye Centre, Dr. Shroff's Charity Eye Hospital, New Delhi, India.
Purpose:
To report endogenous fungal endophthalmitis, postrecovery from severe COVID-19 infection in otherwise immunocompetent individuals, treated with prolonged systemic steroids.
Methods:
Retrospective chart review of cases with confirmed and presumed fungal endogenous endophthalmitis, following severe COVID-19 disease, treated at two tertiary care referral eye institutes in North India.
Results:
Seven eyes of five cases of endogenous fungal endophthalmitis were studied. All cases had been hospitalized for severe COVID-19 pneumonia and had received systemic steroid therapy for an average duration of 42 ± 25.1 days (range 18-80 days). All the cases initially complained of floaters with blurred vision after an average of 6 days (range 1-14 days) following discharge from hospital. They had all been misdiagnosed as noninfectious uveitis by their primary ophthalmologists. All eyes underwent pars plana vitrectomy (PPV) with intravitreal antifungal therapy. Five of the seven eyes grew fungus as the causative organism (Candida sp. in four eyes, Aspergillus sp. in one eye). Postoperatively, all eyes showed control of the infection with a marked reduction in vitreous exudates and improvement in vision.
Conclusion:
Floaters and blurred vision developed in patients after they recovered from severe COVID-19 infection. They had received prolonged corticosteroid treatment for COVID-19 as well as for suspected noninfectious uveitis. We diagnosed and treated them for endogenous fungal endophthalmitis. All eyes showed anatomical and functional improvement after PPV with antifungal therapy. It is important for ophthalmologists and physicians to be aware of this as prompt treatment could control the infection and salvage vision.
Insights
Severe COVID-19 survivors treated with steroids developed fungal endophthalmitis. Prompt diagnosis and pars plana vitrectomy with antifungal therapy improved vision and controlled infection in these cases.
Area of Science:
- Ophthalmology
- Infectious Diseases
- Critical Care Medicine
Background:
- Severe COVID-19 infection can necessitate prolonged systemic steroid use.
- Immunocompetent individuals may develop opportunistic infections post-COVID-19.
- Endogenous fungal endophthalmitis is a rare but serious complication.
Purpose of the Study:
- To report cases of endogenous fungal endophthalmitis following severe COVID-19.
- To highlight the role of prolonged systemic steroid therapy in these cases.
- To describe treatment outcomes and emphasize clinical awareness.
Main Methods:
- Retrospective chart review of five patients with fungal endophthalmitis post-COVID-19.
- Analysis of treatment with pars plana vitrectomy (PPV) and intravitreal antifungal therapy.
- Microbiological analysis of causative fungal species (Candida sp., Aspergillus sp.).
Main Results:
- Seven eyes of five patients presented with blurred vision and floaters 6 days post-discharge.
- All patients had received an average of 42 days of systemic steroids for severe COVID-19.
- Fungal cultures were positive in five eyes; Candida sp. and Aspergillus sp. were identified.
- All eyes showed infection control and vision improvement after PPV and antifungal treatment.
Conclusions:
- Endogenous fungal endophthalmitis can occur in immunocompetent individuals after severe COVID-19 and prolonged steroid use.
- Misdiagnosis as noninfectious uveitis is common.
- Early diagnosis and prompt surgical and antifungal treatment are crucial for visual recovery.
Related Concept Videos
Fungal Phylum Microsporidia
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview
Angle Closure Glaucoma: Treatment
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Endocarditis III: Medical Management

